UPDATE: Jefferies Raises PT on Becton, Dickinson and Co. on Compelling Secular Growth Story
In a report published Thursday, Jefferies analyst Jon Wood reiterated a Buy rating on Becton, Dickinson and Co. (NYSE: BDX), and raised the price target from $96.00 to $107.00.
In the report, Wood noted, “BDX's foray into the generic prefilled injectable drug arena adds a new compelling secular growth story to the investment thesis. With its main competitor enduring chronic manufacturing / QC issues, BDX's ability to leverage its hospital channel presence should help stimulate initial uptake. We are raising our FY14 EPS forecast to $6.25 (from $6.20). Our PT moves to $107 (from $96) on higher intermediate-term cash flow forecasts.”
Becton, Dickinson and Co. closed on Wednesday at $95.16.
Latest Ratings for BDX
|Apr 2017||Evercore ISI Group||Upgrades||In-Line||Outperform|
|Jan 2017||Raymond James||Downgrades||Strong Buy||Outperform|
|Jan 2017||JP Morgan||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.